R. Andrew Harkins, MD, MS
Department of Lymphoma - Myeloma, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Lymphoma and Myeloma, Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Fellow, Hematology and Medical Oncology, Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2020 | Laney Graduate School of Emory University, Atlanta, Georgia, US, Master of Science in Clinical Research |
| 2020 | Emory University School of Medicine, Atlanta, Georgia, US, Medical Doctor |
| 2013 | Georgetown University, Washington, District of Columbia, US, Post-baccalaureate Coursework |
| 2008 | Duke University, Durham, North Carolina, US, Bachelor of Arts |
Postgraduate Training
| 2023-null | Fellow, Hematology and Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2020-2023 | Resident, Internal Medicine, Emory University School of Medicine, Atlanta, Georgia |
Licenses & Certifications
| 2023 | American Board of Internal Medicine |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. LymphoMAPs in Trial Design: Augmenting Bispecific Therapy in rrLBCL with Interferon-Gamma Blockade. Lymphoma/Myeloma Career Development Workshop. Houston, Texas, US.
- 2025. Clinical Applications of LymphoMAPs. Lymphoma/Myeloma Departmental Seminar. Houston, Texas, US.
- 2025. Gastric Cancer in a Patient with Dementia. Fellows' Case Conference. Houston, Texas, US.
- 2024. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. Fellows' Journal Club. Houston, Texas, US.
- 2024. T-DXd in Advanced Solid Tumors with HER2 Amplification Identified by cfDNA: a Multicenter, Single-Arm, Phase II Basket Trial. Thoracic Medical Oncology Journal Club. Houston, Texas, US.
- 2024. NIFE: nal-IRI/FU/LV or G/C in Advanced Cholangiocarcinoma. Gastrointestinal Medical Oncology Journal Club. Houston, Texas, US.
- 2024. Case Presentation: Ocular Lymphoma. Fellows' Case Conference. Houston, Texas, US.
- 2024. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy RPLND with Viable Residual Cancer. Genitourinary Medical Oncology Journal Club. Houston, Texas, US.
- 2024. Association Between Pre-Treatment Emotional Distress and Neoadjuvant Immune Checkpoint Blockade Response in Melanoma. Melanoma Medical Oncology Journal Club. Houston, Texas, US.
- 2023. High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Lymphoma/Myeloma Medical Oncology Journal Club. Houston, Texas, US.
- 2023. The POSITIVE Trial. Breast Medical Oncology Journal Club. Houston, Texas, US.
- 2023. ATLAS-INH: Assessing the Efficacy and Safety of Fitusiran. Benign Hematology Journal Club. Houston, Texas, US.
- 2019. Transgender Health in Clinical Research. Invited. Clinicopathological Conference on Transgender Health. Atlanta, Georgia, US.
- 2019. Entry Criteria for DLBCL Clinical Trials. Invited. Fourth Annual Lymphoma Collaborative Conference. Atlanta, Georgia, US.
National Presentations
- 2025. Improving Clinical Trial Design to Accelerate Drug Approval. Invited. CLL-Lymphoma US Focus Meeting. Santa Monica, California, US.
- 2019. Delphi-Method Survey to Define Essential Eligibility Criteria in First-Line Clinical Trials for DLBCL. Lymphoma Epidemiology of Outcomes (LEO) Study Meeting. Virtual, US.
- 2019. Developing Consensus Eligibility Criteria for First-Line Studies in DLBCL in the LEO Consortium. Lymphoma Epidemiology of Outcomes (LEO) Study Meeting. Virtual, US.
International Presentations
- 2024. Case Presentation: Early-Stage DLBCL. Invited. Preceptorship Program for Visiting Oncologists: Review of DLBCL Management. Houston, US.
- 2024. Case Presentation: Imaging in DLBCL. Invited. Preceptorship Program for Visiting Oncologists: Review of DLBCL Management. Houston, US.
Formal Peers
- 2023. Malignancies in persons living with HIV. Houston, Texas, US.
Grant & Contract Support
| Date: | 2018 - 2019 |
| Title: | NIH/NCATS Georgia Clinical and Translational Science Alliance TL1 Predoctoral Research Training Award |
| Funding Source: | NIH/NCATS |
| Role: | Recipient |
| ID: | TL1TR002381 |
Selected Publications
Peer-Reviewed Articles
- Chihara D, Balakrishnan K, Masand G, Harkins RA, Akkad N, Alekseeva E, Nesmelov A, Shugaev-Mendosa E, Anosov I, Rusinov A, Postovalova E, Gracheva Y, Lauziere K, Paradiso F, Kotlov N, Bagaev A, Green MR, Fowler NH, Flowers CR, Westin JR. Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma. Blood Adv, 2026. e-Pub 2026. PMID: 42498283.
- Li X, Singhal K, Deng Q, Chihara D, Russler-Germain D, Harkins RA, Henderson J, Arita K, Kizhakeyil A, Sun R, Lakra P, Hussein U, Foltz JA, Wilson A, Schmidt E, Nizamuddin I, Dinh T, Kesaraju A, Hamilton MP, Allen C, Gandhi MK, Tobin J, Jiang A, Hilton L, Scott DW, Vega F, Flowers CR, Westin JR, Griffith OL, Fehniger TA, Griffith M, Green MR. Large B-Cell Lymphoma Microenvironment Archetype Profiles. Cancer Cell, 2025. e-Pub 2025. PMID: 40920660.
- Harkins RA, Patel SP, Lee MJ, Switchenko JM, Ansell SM, Bartlett NL, Blum K, Cashen AF, Casulo C, Friedberg JW, Johnston P, Kahl BS, Leonard JP, Link BK, Lossos IS, Martin P, Maurer MJ, Mehta-Shah N, Reagan P, Westin JR, Koff JL, Flowers CR. Improving Eligibility Criteria for First-Line Trials for Patients with DLBCL Using a U.S.-Based Delphi-Method Survey. Blood Adv, 2022. e-Pub 2022. PMID: 35100356.
- Lee MJ, Koff JL, Switchenko JM, Jhaney CI, Harkins RA, Patel SP, Dave S, Flowers CR. Genome-Defined African Ancestry is Associated with Distinct Mutations and Worse Survival in Diffuse Large B-Cell Lymphoma. Cancer, 2020. e-Pub 2020. PMID: 32469082.
- Patel SP, Harkins RA, Lee MJ, Flowers CR, Koff JL. Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk, 2019. e-Pub 2019. PMID: 32063526.
Invited Articles
- Harkins RA, Flowers CR. How Should Clinicians Interpret Conflicting Cost-Effectiveness Analyses for the Treatment of Lymphoma Across Nations and Payer Models?. Leuk Lymphoma, 2020. e-Pub 2020. PMID: 33143518.
Review Articles
- Lee MJ, Abousaud A, Harkins RA, Marin E, Balasubramani D, Churnetski MC, Peker D, Singh A, Koff JL. Important Considerations in the Diagnosis and Management of Post-Transplant Lymphoproliferative Disorder. Curr Oncol Rep, 2023. e-Pub 2023. PMID: 37162742.
- Harkins RA, Patel SP, Flowers CR. Cost-Effectiveness of New Targeted Agents in Chronic Lymphocytic Leukemia. Cancer J, 2019. e-Pub 2019. PMID: 31764123.
- Harkins RA, Patel SP, Flowers CR. Cost Burden of Diffuse Large B-Cell Lymphoma. Expert Rev Pharmacoecon Outcome Res, 2019. e-Pub 2019. PMID: 31623476.
- Harkins RA, Chang A, Patel SP, Lee MJ, Goldstein J, Merdan S, Flowers CR, Koff JL. Remaining Challenges in Predicting Patient Outcomes for Diffuse Large B-Cell Lymphoma. Expert Rev Hematol, 2019. e-Pub 2019. PMID: 31513757.
Abstracts
- Patel SP, Harkins RA, Lee MJ, Flowers CR. Using Informatics Tools to Characterize Precision Medicine Treatments for Diffuse Large B-Cell Lymphoma (DLBCL). American Society of Hematology Annual Meeting and Exposition.
- Harkins RA, Flowers CR. Defining Parsimonious Eligibility Criteria in Precision Medicine Clinical Trials for Diffuse Large B-Cell Lymphoma. Association for Clinical and Translational Science (ACTS) Translational Science Conference.
- Harkins RA, Patel SP, Lee MJ, Switchenko JM, Flowers CR. A Data-Driven Approach to Define Parsimonious Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma. American Society of Hematology Annual Meeting and Exposition.
- Harkins RA, Tejani MN, Henry TL, George MR. High-Risk Counties in Rural Georgia Where Cancer Treatment is Likely to be Affected by Proposed Cuts to the 340B Drug Pricing Program. 10th Annual Emory University School of Medicine Social Medicine Forum.
- Coleman CG, Massie AM, Harkins RA, Wigger GW, Daniels LM. Double Trouble with Olanzapine Overdose. American Thoracic Society International Conference.
- Lee MJ, Koff JL, Hildebrandt MAT, Switchenko JM, Jhaney CI, Harkins RA, Patel SP, Dave SS, Flowers CR. Mutational Landscape of Diffuse Large B-Cell Lymphoma in Patients with Genome-Defined African Ancestry. 13th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved.
- Harkins RA, Flowers CR. Modernizing Eligibility Criteria in First-Line Clinical Trials for Diffuse Large B-Cell Lymphoma: Consensus Recommendations Using a Modified Delphi-Method Survey. American Society of Hematology Annual Meeting and Exposition.
- Harkins RA, Rollin FG. Acute Parotitis Associated with COVID-19: A Case Report. 18th Annual Department of Medicine Resident Research Day.
- Chihara D, Balakrishnan K, Masand G, Harkins RA, Akkad N, Novokreshchenova A, Bagaev A, Kotlov N, Postovalova E, Shugaev-Mendosa E, Gracheva Y, Lauziere K, Kaneunyenye L, McKenna B, Berlinski A, Walsh M, Larson L, Kotsinyan M, Samokhina A, Yong S, Nomie K, Fowler N, Flowers CR, Westin J. Evaluating the Clinical Utility of Real-Time Comprehensive Whole Exome Sequencing and RNA-Seq for Patients with Diffuse Large B-Cell Lymphoma. American Society of Hematology Annual Meeting and Exposition.
- Harkins RA, Chihara D, Flowers CR. Collective Analysis of Genomic Data Sets to Assess the Impact of Eligibility Criteria on Molecular Subsets in First-Line Clinical Trials for Patients with Diffuse Large B-Cell Lymphoma. American Society of Hematology Annual Meeting and Exposition.
Patient Reviews
CV information above last modified September 03, 2026